

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION											
DISTRICT ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032 Rockville, MD 20857		DATE(S) OF INSPECTION 11/13/2023-11/17/2023 FEI NUMBER 3005260401									
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Tao NMN Zeng , General Manager											
FIRM NAME Jiangsu Intco Medical Products Co., Ltd.		STREET ADDRESS 298 Yandunshan Road, Dagangzhen Jingkou									
CITY, STATE, ZIP CODE, COUNTRY Zhenjiang, Jiangsu, 212132 China		TYPE ESTABLISHMENT INSPECTED OTC Drug Manufacturer									
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.											
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: PRODUCTION SYSTEM											
OBSERVATION 1 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. Specifically, Your firm failed to retain records to support your process validation for OTC (b) (4) manufacturing. You did not maintain batch production records used as part of you process performance qualification for your OTC liquid (b) (4) at (b) (4)% and OTC gel (b) (4) at (b) (4)%. The following batches were used to for your process validation; however, your firm did not retain these records in support of your validation: <table border="1" style="margin-left: auto; margin-right: auto; border-collapse: collapse; text-align: center;"> <thead> <tr> <th style="padding: 5px;">Product</th> <th style="padding: 5px;">Batch 1</th> <th style="padding: 5px;">Batch 2</th> <th style="padding: 5px;">Batch 3</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="height: 100px; vertical-align: middle; font-size: 48px; font-weight: bold;">(b) (4)</td> </tr> </tbody> </table>				Product	Batch 1	Batch 2	Batch 3	(b) (4)			
Product	Batch 1	Batch 2	Batch 3								
(b) (4)											
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Khoa Nathan V Tran, Investigator Crystal Monroy, Investigator Crystal Monroy Investigator Signed By: 2003060870 Date Signed: 11-17-2023 1125:32									
DATE ISSUED 11/17/2023											
FORM FDA 483 (09/08)		PREVIOUS EDITION OBSOLETE									
INSPECTIONAL OBSERVATIONS		PAGE 1 of 4 PAGES									

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION											
DISTRICT ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032 Rockville, MD 20857		DATE(S) OF INSPECTION 11/13/2023-11/17/2023 FEI NUMBER 3005260401									
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Tao NMN Zeng , General Manager											
FIRM NAME Jiangsu Intco Medical Products Co., Ltd.		STREET ADDRESS 298 Yandunshan Road, Dagangzhen Jingkou									
CITY, STATE, ZIP CODE, COUNTRY Zhenjiang, Jiangsu, 212132 China		TYPE ESTABLISHMENT INSPECTED OTC Drug Manufacturer									
LABORATORY SYSTEM											
OBSERVATION 2 There is no written testing program designed to assess the stability characteristics of drug products. Specifically, Your firm's stability program is deficient. For example: (a) You did not maintain batch production records used to support your stability testing used to establish a (b) (4) expiration date for your OTC liquid (b) (4) at (b) (4) % and OTC gel (b) (4) at (b) (4) %. The following batches were used for your accelerated and long-term stability study, however your firm did not maintain the batch records and destroyed them on February 10, 2023. <table border="1" style="width: 100%; border-collapse: collapse; margin: 10px 0;"> <thead> <tr> <th style="width: 35%;">Product</th> <th style="width: 15%;">Batch 1</th> <th style="width: 15%;">Batch 2</th> <th style="width: 35%;">Batch 3 cm 11/17/2022</th> </tr> </thead> <tbody> <tr> <td colspan="4" style="height: 100px; text-align: center; vertical-align: middle; font-size: 48px; background-color: #cccccc;">(b) (4)</td> </tr> </tbody> </table> (b) Your firm failed to evaluate the stability of OTC (b) (4) in the container-closure system in which they are being marketed. You manufacture liquid (b) (4) products in the following configuration: (b) (4) oz. However, you only conducted stability testing for liquid (b) (4) (b) (4) in the (b) (4) oz configuration and you do not have data to support the expiration date in your liquid (b) (4) products in (b) (4) oz configurations.				Product	Batch 1	Batch 2	Batch 3 cm 11/17/2022	(b) (4)			
Product	Batch 1	Batch 2	Batch 3 cm 11/17/2022								
(b) (4)											
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Khoa Nathan V Tran, Investigator Crystal Monroy, Investigator DATE ISSUED 11/17/2023 Crystal Monroy Investigator Signed By: 2003060670 Date Signed: 11-17-2023 11:25:32 X									
FORM FDA 483 (09/08)		PREVIOUS EDITION OBSOLETE									
		INSPECTIONAL OBSERVATIONS									
		PAGE 2 of 4 PAGES									

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032 Rockville, MD 20857		DATE(S) OF INSPECTION 11/13/2023-11/17/2023 FEI NUMBER 3005260401	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Tao NMN Zeng , General Manager			
FIRM NAME Jiangsu Intco Medical Products Co., Ltd.		STREET ADDRESS 298 Yandunshan Road, Dagangzhen Jingkou	
CITY, STATE, ZIP CODE, COUNTRY Zhenjiang, Jiangsu, 212132 China		TYPE ESTABLISHMENT INSPECTED OTC Drug Manufacturer	
MATERIALS SYSTEM			
OBSERVATION 3 Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed. Specifically, Drug components used in the manufacture of (b) (4) products lack identification testing. For example, your firm does not perform spectroscopic identification tests and limit of (b) (4) for (b) (4) or spectroscopic identification tests and limit of (b) (4) for (b) (4). Each assessment is described as an identification test per the material's USP monograph.			
OBSERVATION 4 Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals. Specifically, a) Your firm has never fully tested a drug component supplier's certificate of analysis for any (b) (4) (b) (4) drug components. b) Your firm qualified (b) (4) suppliers despite not having fully performed testing of drug components per USP.			
SEE REVERSE OF THIS PAGE		EMPLOYEE(S) SIGNATURE Khoa Nathan V Tran, Investigator Crystal Monroy, Investigator Crystal Monroy Investigator Signed By: 2003080870 Date Signed: 11-17-2023 11:26:32 X	
DATE ISSUED 11/17/2023			

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER 12420 Parklawn Drive, Room 2032 Rockville, MD 20857		DATE(S) OF INSPECTION 11/13/2023-11/17/2023	
		FEI NUMBER 3005260401	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Tao NMN Zeng , General Manager			
FIRM NAME Jiangsu Intco Medical Products Co., Ltd.		STREET ADDRESS 298 Yandunshan Road, Dagangzhen Jingkou	
CITY, STATE, ZIP CODE, COUNTRY Zhenjiang, Jiangsu, 212132 China		TYPE ESTABLISHMENT INSPECTED OTC Drug Manufacturer	
X Khoa Nathan V Tran Investigator Signed By: 2003026741 Date Signed: 11-17-2023 11:25:08			
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Khoa Nathan V Tran, Investigator Crystal Monroy, Investigator		DATE ISSUED 11/17/2023
	X Crystal Monroy Investigator Signed By: 2003060670 Date Signed: 11-17-2023 11:26:52		
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 4 of 4 PAGES			